The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Alzheimer's disease failed clinical trials
Abstract
Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the Aβ plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Second-generation anti-amyloid antibody against soluble monomeric Aβ (solanezumab), insoluble monomeric Aβ (gantenezumab), and monoclonal antibody against multiple Aβ forms (crenezumab) failed to have efficacy in improving cognitive functions for mild and moderate AD in several clinical trials (Table 2, for example [36]).”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [36]
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
The Episodic Memory System: Neurocircuitry and Disorders
Dickerson, B. C., & Eichenbaum, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 740
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Research works printed but not linked: 1
- Schindowski, 2014, Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations, Degener. Neurol. Neuromuscul. Dis., 4, 121
Cited by
Sorted by citations
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
Choudhury, C., Goel, T., & Tanveer, M. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102415 · Cited by 52
Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?
Ruggiero, M., Calvello, R., Porro, C., Messina, G., Cianciulli, A., & Panaro, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112958 · Cited by 59
Jiang, J., Pan, H., Shen, F., Tan, Y., & Chen, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373715 · Cited by 50
Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?
Balistreri, C. R., & Monastero, R. (2023) · Brain Sciences · doi:10.3390/brainsci14010019 · Cited by 47
Metadata
- Authors
- Asher, S., & Priefer, R.
- Affiliations
- Massachusetts College of Pharmacy and Health Sciences (US)
- Corresponding author
- Priefer, Ronny
- ORCID
- Priefer, Ronny
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 306
- Pages
- 120861
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W4289732088
- Cited by
- 124
- References
- 61
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 34 · 2023: 29 · 2022: 8
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Life Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, clinical trial failure, amyloid plaques, tau tangles, anti-amyloid therapy, anti-tau therapy, cognitive function, neurodegeneration, therapeutic target
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Amyloid beta-Peptides, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
